DelveInsight’s “Corticobasal Degeneration (CBD) – Market Insight, Epidemiology And Market Forecast – 2032” report delivers an in-depth understanding of this rare neurological disorder, including historical and forecasted epidemiology as well as corticobasal degeneration market trends across the 7MM. The report provides detailed insights into current treatment practices, emerging drugs, market share of individual therapies, and forecasted market size till 2032, along with an assessment of corticobasal degeneration market drivers, barriers, and unmet medical needs that could influence future market dynamics.
The corticobasal degeneration market is expected to experience steady growth across 7MM, driven by a rising awareness, earlier diagnosis, and a shift in treatment strategies from purely symptomatic management to more personalized and disease-modifying approaches, including ongoing research into neuroprotective and gene therapies. The increasing elderly population is also contributing to higher demand for corticobasal degeneration therapies.
Download the corticobasal degeneration market report to understand which factors are driving the corticobasal degeneration therapeutic market @ Corticobasal Degeneration Market Trends.
Furthermore, the US currently represents the largest corticobasal degeneration patient pool and market share within the 7MM. While current treatments primarily focus on alleviating symptoms, advancements in clinical research and the development of innovative drugs are expected to further shape the market landscape, addressing unmet medical needs and improving patient outcomes.
DelveInsight’s epidemiological studies indicate that corticobasal degeneration remains a rare neurodegenerative disorder across the 7MM, but the number of diagnosed cases is gradually increasing due to improved awareness and better diagnostic tools. Most patients are over 60 years old, and the aging population in these countries is expected to lead to a slow and steady rise in prevalence. The age of symptom onset ranges between 45 and 72.2 years, with a mean of 63.7 years. Furthermore, the mean survival is estimated between 6 to 8 years following diagnosis, highlighting the progressive and ultimately fatal nature of this disorder.
The United States has the highest number of diagnosed cases, while European countries and Japan are also seeing more cases as doctors become more familiar with the disease. However, corticobasal degeneration is still often underdiagnosed or mistaken for similar conditions, highlighting the need for continued education and research.
Discover evolving trends in the corticobasal degeneration patient pool forecasts @ Corticobasal Degeneration Epidemiology Analysis.
The DelveInsight’s corticobasal degeneration market report also analyses the current and emerging treatment landscape. The current treatments are directed at symptom management, rather than disease management. Approximately 92% of patients receive dopaminergic drugs, though only about 24% show beneficial effects, primarily for Parkinsonian symptoms. Other management approaches include benzodiazepines for myoclonus and dystonia, botulinum toxin injections for focal dystonia, and various other symptomatic treatments with limited efficacy. The significant gap in effective treatment options represents a substantial market opportunity for pharmaceutical companies developing novel therapies targeting the underlying pathophysiology of the disease.
The corticobasal degeneration pipeline is showing promising development with several experimental therapies advancing through the pipeline, most aiming to clear or neutralize pathological tau. Bepranemab (UCB0107), manufactured by UCB (EBR: UCB) is a monoclonal antibody under open‐label safety evaluation. NIO752, manufactured by Novartis (SWX: NOVN), is an intrathecally administered antisense oligonucleotide against tau and is in Phase I trials. An oral Rho kinase inhibitor designed to boost tau clearance via autophagy is active in Phase IIa studies. RAVICTI by Hyperion Therapeutics (NASDAQ: HPTX) is recruiting for a Phase II trial to enhance microglial phagocytosis of tau aggregates. Nicotinamide riboside, a NAD+ precursor thought to support neuronal health, is slated for Phase II testing.
The competitive landscape in corticobasal degeneration treatment is shaped by companies including ProMIS Neurosciences, Neural Stem Cell Institute, and Cortice Biosciences developing experimental therapies, alongside Biogen, which advanced the anti-tau antibody gosuranemab through clinical trials.
Recent advances in the corticobasal degeneration (CBD) field span regulatory milestones in diagnostic imaging, updates on key clinical trials, and promising preclinical therapeutic findings.
In March 2024, the FDA granted permission for the tau PET ligand 18F-APN-1607 to enter a Phase III clinical trial evaluating its ability to detect 4-repeat tau pathologies in early or diagnostically equivocal CBD and progressive supranuclear palsy (PSP) patients.
In November 2024, a study identified FDA-approved carbonic anhydrase inhibitors-most notably the glaucoma drug methazolamide, as agents that enhance lysosomal exocytosis to clear toxic tau proteins and reduce neurodegeneration in tauopathy models, offering a potential repurposed treatment pathway for CBD.
The recent approval of disease-modifying therapies for related neurodegenerative conditions like Alzheimer’s disease has invigorated interest in developing similar approaches for other proteinopathies, including corticobasal degeneration. This momentum is expected to accelerate the development of novel therapeutic options over the forecast period.
Discover recent advancements in the corticobasal degeneration treatment landscape @ Corticobasal Degeneration Recent Developments.
Looking ahead, the corticobasal degeneration market is anticipated to evolve significantly as research continues to uncover the molecular intricacies of the disease and novel therapeutic approaches move through clinical development. The integration of advanced diagnostic technologies, including artificial intelligence in neuroimaging and molecular biomarkers, is expected to enhance the accuracy of diagnosis and patient stratification for clinical trials.
As understanding of the genetic and neuropathological diversity of corticobasal syndrome expands, there is growing optimism for the development of more effective disease-modifying treatments that could significantly impact patient outcomes and reshape the treatment paradigm for this challenging neurological disorder in the coming decade.
Table of Contents
1. Key Insights
2. Executive Summary of Corticobasal Degeneration
3. Competitive Intelligence Analysis for Corticobasal Degeneration
4. Corticobasal Degeneration: Market Overview at a Glance
5. Corticobasal Degeneration: Disease Background and Overview
6. Patient Journey
7. Corticobasal Degeneration Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Corticobasal Degeneration Unmet Needs
10. Key Endpoints of Corticobasal Degeneration Treatment
11. Corticobasal Degeneration Marketed Products
12. Corticobasal Degeneration Emerging Therapies
13. Corticobasal Degeneration: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Corticobasal Degeneration (CBD)
17. KOL Views
18. Corticobasal Degeneration Market Drivers
19. Corticobasal Degeneration Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Corticobasal Degeneration Pipeline Insight
Corticobasal Degeneration Pipeline Insight provides comprehensive insights about the CBD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the corticobasal degeneration companies, including Asahi Kasei, Tapestry Pharmaceuticals, and AC Immune, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Arpit AnandEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
